Revista Médica del Instituto Mexicano del Seguro Social

Contents by Year, Volume and Issue

Table of Contents

General Information

Instructions for Authors

Message to Editor

Editorial Board

>Journals >Revista Médica del Instituto Mexicano del Seguro Social >Year 2004, Issue 4

Velasco RVM, Padua GA, Esquivel MC, Sánchez CO, Martínez OV, Cicero SR
Epidemiology and Initial Resistance to Antituberculous Drugs in Cases of Lung Tuberculosis
Rev Med Inst Mex Seguro Soc 2004; 42 (4)

Language: Español
References: 29
Page: 303-308
PDF: 131.04 Kb.

Full text


We selected a cohort of 62 new cases of pul-monary tuberculosis in 2000 from the Mexican Institute of Social Security’s (IMSS) Hospital of the Comarca Lagunera in the northern state of Coahuila, Mexico, for clinical and sociodemographic study. All were treated with isoniacid (H) rifampin (R), a pirazinamide (Z) for 6 months with a 1-year follow-up. Acid fast bacilli (AFB) in sputum samples were taken monthly. We carried out identification and drug susceptibility of Mycobacterium tuberculosis in 22 cultures. Mean age among cases was 42 ± 12.5 years, 89% had an elementary school education and low income, bacille Calmette-Guérin (BCG) vaccination was recorded in 50%, but 40.3 % had other concurrent diseases, mainly diabetes mellitus. One case had HIV-AIDS. Among the 22 cultured cases, there was initial resistance in seven (32%), including four with resistance to one drug (three to S, one to Z), and three to two drugs (one each of H + S, H + Z, and H + R). Sixty nine percent of patients were cured, deaths constituted 10%, and noncompliance, 13 %, while AFB persisted in 8 %. Diabetes was most frequently associated with treatment failure. Healing rate was less than that previously reported in Mexico, while low supervision and initial resistance reported in seven of 22 cases were similar to rates in other Mexican states. New diagnostic and treatment strategies for tuberculosis are needed, together with reinforcement of already established programs.

Key words: tuberculosis, pulmonary, tuberculosis, multidrug-resistant.


  1. World Health Organization. Global tuberculosis control. WHO Report 2001. WHO/CDS/TB/2001. 287. Geneva, Switzerland: WHO; 2001.

  2. 2. Instituto Nacional de Estadística, Geografía e Informática. Estadísticas del Sector Salud y Seguridad Social. Cuaderno 18. México: INEGI; 2001.

  3. 3. American Thoracic Society. Diagnostic standards and classification of tuberculosis in adults and chil-dren. Am J Resp Crit Care Med 2000;161:1376-1395.

  4. 4. Milian F, Sánchez LM, Toledo P, Ramírez C, San-tillán MA. Descriptive study of human and bovine tuberculosis in Querétaro, México. Rev Latinoam Microbiol 2000;42:13-19.

  5. 5. Bustamante MLP, Bellido-Bárcenas F, Rojas-Rodríguez H, Borja-Aburto VH, Yáñez-Velasco L, Becerra-Posada F. Características sociodemográficas de personas que murieron por tuberculosis pulmonar en Veracruz, México, 1993. Salud Publica Mex 1996;38:323-331.

  6. 6. Canales R, Coulson F, East J. Pulmonary tuberculosis and multidrug resistance. Epidemiologic review and management. Physician Assistant 2001;25:25.

  7. 7. Pablos-Méndez A, Raviglione MC, Laslo A, Binkin N, Rieder HL, Bustreo F, Cohn DL, Lambregts-Van Weezenbeek CSB, Kim SJ, Chaulet P, Nunn P. Glo-bal surveillance for antituberculosis-drug resistance, 1994-1997. World Health Organization International Union Against Tuberculosis and Lung Diseases Wor-king Group on Antituberculosis Drug Resistance Surveillance. N Engl J Med 1998;338:1641-1649.

  8. 8. Granich RM, Balandrano S, Santaella AJ, Binkin NJ, Castro KG, Márquez-Fiol A, et al. Survey of drug resistance of Mycobacterium tuberculosis in three Mexican states, 1997. Arch Intern Med 2000; 160:639-644.

  9. 9. Ponce-de León A. Resistencia a antimicrobianos en tuberculosis: mecanismos y opciones terapéuticas. Rev Invest Clin 2000;52:72-79.

  10. Bastian I, Colebinders R. Treatment and preven-tion of multidrugresistant tuberculosis. En: Peters DC, editor. Fighting the scourge of tuberculosis. Auckland: Adis Int. Ltd.; 2000. p. 11-42.

  11. Granich RM, Moore M, Binken NJ, Mcray E. Drug resistant tuberculosis in foreign-born persons from Mexico, the Philippines, and Vietnam-United States, 1993-1997. Int J Tuberc Lung Dis 2001;5:53-58.

  12. Álvarez-Gordillo GC, Sandoval-Trujillo H, Bojalil- Jaber LF. Tuberculosis resistant to treatment with antituberculosis drug. A study in the state of Chiapas, México. Atencion Primaria 1999;24(4):209-214.

  13. García-García ML, Jiménez-Corona MF, Ponce-de León A, Jiménez-Corona A, Palacios-Martínez M, Balandrano-Campos S, Ferreira-Reyes L, Juárez-Sandino L, Sifuentes-Osornio J, Olvera-Diez H, Valdespino-Gómez JL, Small PM. Mycobaterium tuberculosis drug resistance in a suburban com-munity in Southern Mexico. Int J Tuberc Lung Dis 2000;4(12 Suppl 2):168-170.

  14. Secretaría de Salud. Reporte epidemiológico de la ciudad de Torreón, Coahuila. Jurisdicción Sanitaria 6. México: SSa; 1999.

  15. Secretaría de Salud. Reporte epidemiológico de la ciudad de Torreón, Coahuila. Jurisdicción Sanitaria 6. México: SSa; 2000.

  16. Blancarte-Meléndez L, Anzaldo-de Jaime G, Balandrano-de Spindola S. Manual de técnicas y procedimientos de laboratorio en tuberculosis. México: Secretaría de Salud, Publicación Técnica del INDRE 20; 1992.

  17. Castillo-de Sánchez ML, Fonseca-Llerena ME. Mejora continua de la calidad. Guía para los laboratorios clínicos de América Latina. México: Panamericana; 1996. p. 25-107.

  18. Smith H. Paradoxical responses during the chemo-therapy of tuberculosis. (Editorial). J Infect 1987;15:1-3

  19. Dooley DP, Carpenter JL, Rademacher S. Adjunctive corticosteroid therapy for tuberculosis: a critical reappraisal of the literature. Clin Infect Dis 1997;25 (4):872-887.

  20. Pablos-Méndez A, Blustein J, Khirsch ChA. The role of diabetes mellitus in the higher prevalence of tubercu-losis among Hispanics. Am J Pub Health 1997;87:574-579.

  21. Center for Disease Control and Prevention. Preven-tion and treatment of tuberculosis among patients infected with human immunodeficiency virus. Principles of therapy and revised recommendations. MMWR 1998;47(RR20):1-58.

  22. Decker C, Lazarus A. Tuberculosis and HIV infection. How to safely treat both disorders concurrently. Postgrad Med 2000;108:57-66.

  23. Dyec C, Scheele S, Dolin P, Pathania V, Raviglione MC. Global burden of tuberculosis. Estimated in-cidence, prevalence and mortality by country. JAMA 1999; 282:677-686.

  24. Lazarus A, Sanders J. Management of tuberculosis choosing an effective regimen and ensuring com-pliance. Postgrad Med 2000;108:71-84.

  25. Chaulk CP, Kazandzian VA. Directly observed therapy for treatment completion of pulmonary tu-berculosis: concensus statement of the public health tuberculosis guidelines panel. JAMA 1998;279:943-948.

  26. Gasner MR, Maw KL, Feldman GE. The use of legal action in New York City to ensure treatment of tu-berculosis. N Engl J Med 1999;340:359-366.

  27. WHO/IUATLD Global Working Group on Anti-tuberculosis Drug Resistance Surveillance. Guidelines for surveillance of drug resistance in tuberculosis. WHO. Geneva/IUATLD Paris. Int Tuber Lung Dis 1998;2:72-89.

  28. Van Rie A, Warren R, Richardson M, Gie RP, Enarson DA, Beyers N, Van Heiden P. Classification of drug-resistant tuberculosis in an epidemic area. Lancet 2000;356:22-25.

  29. Secretaría de Salud. Norma oficial mexicana: Modificación NOM-006-SSA2-1993 para la pre-vención y control de la tuberculosis en la atención primaria a la salud. Diario Oficial de la Federa-ción 2000;18:9-33.

>Journals >Revista Médica del Instituto Mexicano del Seguro Social >Year 2004, Issue 4

· Journal Index 
· Links 

Copyright 2019